Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia (NCT06584357)
🩺 Plain-English Summary (8th-Grade Level)
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.
Who can join: Review the eligibility criteria below.
Location: JEM Research Institute — Atlantis, Florida
Age range: 60 Years to 90 Years
🧪 Interventions in This Study
- Biomarker Data Collection (OTHER)
- MK6240 (RADIATION)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- JEM Research Institute — Atlantis, Florida
- Visionary Investigators Network — Aventura, Florida
- K2 - Winter Garden — Clermont, Florida
- Brain Matters Research — Delray Beach, Florida
- Neuropsychiatric Research Center of SW Florida — Fort Myers, Florida
- K2 Medical Research — Maitland, Florida
- Clincloud — Melbourne, Florida
- Visionary Investigators Network — Miami, Florida
- Charter Research — Orlando, Florida
- Progressive Medical Research — Port Orange, Florida
- Intercoastal Medical Group, Inc. — Sarasota, Florida
- Axiom Brain Health — Tampa, Florida
- Conquest Research — Winter Park, Florida
- Flourish Research - Chicago — Chicago, Illinois
- Quest Research Institute — Farmington Hills, Michigan
- Clinical Neurology Specialists — Las Vegas, Nevada
- ADRC of Albany — Albany, New York
- Neuro-Behavioral Clinical Research Inc. — North Canton, Ohio
- Flourish Research - Philadelphia — Philadelphia, Pennsylvania
- K2 Medical Research — East Providence, Rhode Island
- Gadolin Research LLC — Beaumont, Texas
- Re:Cognition Health — Houston, Texas
- Toronto Memory Program — Toronto, Ontario
- NeuroClin Glasgow — Motherwell, North Lanarkshire
- Re:Cognition Health — London,
📞 Contact the Study Coordinator
Phone: (561) 968-2933
Email: emcbride@jemri.net
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Mild Cognitive Impairment
- Enhancing Frontal Lobes Plasticity in Mild Cognitive Impairment — Toronto, Ontario
- Remote Game-based Exercise Program for Cognitive and Motor Function Improvement — Los Angeles, California
- Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD) — Boston, Massachusetts
- Glutathione in Mild Cognitive Impairment — Houston, Texas
- Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy — Morgantown, West Virginia
- Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease — Los Angeles, California
Explore by condition: All Mild Cognitive Impairment clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.